Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.

Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM.

J Hepatol. 2014 Sep;61(3):515-22. doi: 10.1016/j.jhep.2014.04.029. Epub 2014 May 2.

PMID:
24798617
[PubMed - in process]
2.

Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.

Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW.

Antivir Ther. 2011;16(8):1249-57. doi: 10.3851/IMP1921.

PMID:
22155906
[PubMed - indexed for MEDLINE]
3.

Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.

Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z, Zhu M, Wong VW, Chan HL.

Aliment Pharmacol Ther. 2011 Aug;34(3):344-52. doi: 10.1111/j.1365-2036.2011.04738.x. Epub 2011 Jun 14.

PMID:
21671967
[PubMed - indexed for MEDLINE]
4.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
[PubMed - indexed for MEDLINE]
5.

A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.

Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C.

Turk J Gastroenterol. 2004 Mar;15(1):14-20.

PMID:
15264116
[PubMed - indexed for MEDLINE]
6.

Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.

Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I.

Z Gastroenterol. 2011 Nov;49(11):1463-9. doi: 10.1055/s-0031-1281582. Epub 2011 Nov 8.

PMID:
22069045
[PubMed - indexed for MEDLINE]
7.

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ.

Clin Gastroenterol Hepatol. 2007 Dec;5(12):1462-8.

PMID:
18054753
[PubMed - indexed for MEDLINE]
8.

Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.

Su CW, Wu CY, Hung HH, Wu CH, Sheen IJ, Wu JC.

J Gastroenterol Hepatol. 2013 Dec;28(12):1849-58. doi: 10.1111/jgh.12283.

PMID:
23730852
[PubMed - indexed for MEDLINE]
9.

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.

J Viral Hepat. 2010 Jan;17(1):16-22. doi: 10.1111/j.1365-2893.2009.01146.x. Epub 2009 Jul 19.

PMID:
19622117
[PubMed - indexed for MEDLINE]
10.

Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.

Lee MH, Lee da M, Kim SS, Cheong JY, Cho SW.

J Med Virol. 2011 Jul;83(7):1178-86. doi: 10.1002/jmv.22089.

PMID:
21567421
[PubMed - indexed for MEDLINE]
11.

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.

Hepatology. 2009 Apr;49(4):1141-50. doi: 10.1002/hep.22760.

PMID:
19338056
[PubMed - indexed for MEDLINE]
12.

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, Yuen MF.

Am J Gastroenterol. 2009 Aug;104(8):1940-6; quiz 1947. doi: 10.1038/ajg.2009.200. Epub 2009 May 19.

PMID:
19455108
[PubMed - indexed for MEDLINE]
13.

Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.

He D, Guo S, Chen W, Chen X, Yan G, Wang J, Li M, Zhu P, Huang H, Wang Y.

BMC Infect Dis. 2013 Oct 3;13:458. doi: 10.1186/1471-2334-13-458.

PMID:
24090287
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.

Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K.

J Viral Hepat. 2012 Mar;19(3):220-6. doi: 10.1111/j.1365-2893.2011.01542.x. Epub 2011 Oct 19.

PMID:
22329377
[PubMed - indexed for MEDLINE]
15.

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH.

Gastroenterology. 2011 Aug;141(2):517-25, 525.e1-2. doi: 10.1053/j.gastro.2011.04.046. Epub 2011 Apr 28.

PMID:
21672542
[PubMed - indexed for MEDLINE]
16.

Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B.

Tangkijvanich P, Komolmit P, Mahachai V, Sa-Nguanmoo P, Theamboonlers A, Poovorawan Y.

Hepatol Res. 2010 Apr;40(4):269-77. doi: 10.1111/j.1872-034X.2009.00592.x. Epub 2010 Jan 11.

PMID:
20070399
[PubMed]
17.

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.

Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.

Antivir Ther. 2012;17(1):9-17. doi: 10.3851/IMP1887.

PMID:
22267464
[PubMed - indexed for MEDLINE]
18.

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.

J Hepatol. 2013 Dec;59(6):1153-9. doi: 10.1016/j.jhep.2013.07.017. Epub 2013 Jul 18.

PMID:
23872601
[PubMed - in process]
19.

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.

van Nunen AB, Hansen BE, Suh DJ, Löhr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW.

Gut. 2003 Mar;52(3):420-4.

PMID:
12584227
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.

Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD.

Hepatobiliary Pancreat Dis Int. 2004 May;3(2):188-93.

PMID:
15138107
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk